Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma
Combined hepatocellular-cholangiocarcinoma (HCC-CCA) is a rare liver malignancy distinct from either hepatocellular carcinoma (HCC) or cholangiocarcinoma. Liver transplantation (LT) is not recommended for HCC-CCA because of suboptimal outcomes. Non-invasive diagnosis of HCC-CCA is extremely challeng...
Saved in:
Published in | Annals of hepatology Vol. 17; no. 6; pp. 969 - 10 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Mexico
01.11.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Combined hepatocellular-cholangiocarcinoma (HCC-CCA) is a rare liver malignancy distinct from either hepatocellular carcinoma (HCC) or cholangiocarcinoma. Liver transplantation (LT) is not recommended for HCC-CCA because of suboptimal outcomes. Non-invasive diagnosis of HCC-CCA is extremely challenging; thus, some HCC-CCAs are presumed as HCC on imaging and listed for LT with the correct diagnosis ultimately made on explant pathology. We compared HCC-CCA with HCC to determine the utility of response to pre-transplant loco-regional therapy (LRT) in predicting outcomes for HCC-CCA after LT as a potential means of identifying appropriate HCC-CCA patients for LT.
Retrospective review of 19 patients with pathologically confirmed HCC-CCA were individually matched to 38 HCC patients (1:2) based on age, sex, and Milan criteria at listing was performed. The modified response evaluation criteria in solid tumors was used to categorize patients as responders or non-responders to pre-transplant LRT based on imaging performed before and after LRT. Overall survival (OS) and recurrence-free survival (RFS) were examined.
OS at 3 years post-transplant was 74% for HCC-CCA and 87% for HCC. RFS at 3 years was 74% for HCC-CCA, and 87% for HCC. Among responders to LRT, the 3-year OS was 92% for HCC-CCA and 88% for HCC; among non-responders, 3-year OS was 43% for HCC-CCA and 83% for HCC. Higher 3-year OS was observed among HCC-CCA responders (77%) compared with HCC-CCA non-responders (23%).
OS was similarly high among responders to pre-transplant LRT irrespective of tumor type. Radiologic response to LRT could potentially be used to select appropriate HCC-CCA patients for LT if the findings are validated in independent studies. |
---|---|
AbstractList | Introduction and aim: Combined hepatocellular-cholangiocarcinoma (HCC-CCA) is a rare liver malignancy distinct from either hepatocellular carcinoma (HCC) or cholangiocarcinoma. Liver transplantation (LT) is not recommended for HCC-CCA because of suboptimal outcomes. Because non-invasive diagnosis of HCC-CCA is extremely challenging, some HCC-CCAs are presumed as HCC on imaging and listed for LT with the correct diagnosis ultimately made on explant pathology. We compared HCC-CCA with HCC to determine the utility of response to pre-transplant loco-regional therapy (LRT) in predicting outcomes for HCC-CCA after LT as a potential means of identifying appropriate HCC-CCA patients for LT. Materials and methods: Retrospective review of 19 patients with pathologically confirmed HCC-CCA individually matched to 38 HCC patients based on age, sex, and Milan criteria at listing was performed. The modified response evaluation criteria in solid tumors was used to categorize patients as responders or non-responders to pre-transplant LRT based on imaging performed before and after LRT. Overall survival (OS) and recurrence-free survival (RFS) were examined. Results: OS at 3 years post-transplant was 74% for HCC-CCA and 87% for HCC. RFS at 3 years was 74% for HCC-CCA, and 87% for HCC. Among responders to LRT, the 3-year OS was 92% for HCC-CCA and 88% for HCC; among non-responders, 3-year OS was 43% for HCC-CCA and 83% for HCC. Higher 3-year OS was observed among HCC-CCA responders (77%) compared with HCC-CCA non-responders (23%). Conclusions: OS was similarly high among responders to pre-transplant LRT irrespective of tumor type. Radiologic response to LRT could potentially be used to select appropriate HCC-CCA patients for LT if the findings are validated in independent studies. Combined hepatocellular-cholangiocarcinoma (HCC-CCA) is a rare liver malignancy distinct from either hepatocellular carcinoma (HCC) or cholangiocarcinoma. Liver transplantation (LT) is not recommended for HCC-CCA because of suboptimal outcomes. Non-invasive diagnosis of HCC-CCA is extremely challenging; thus, some HCC-CCAs are presumed as HCC on imaging and listed for LT with the correct diagnosis ultimately made on explant pathology. We compared HCC-CCA with HCC to determine the utility of response to pre-transplant loco-regional therapy (LRT) in predicting outcomes for HCC-CCA after LT as a potential means of identifying appropriate HCC-CCA patients for LT. Retrospective review of 19 patients with pathologically confirmed HCC-CCA were individually matched to 38 HCC patients (1:2) based on age, sex, and Milan criteria at listing was performed. The modified response evaluation criteria in solid tumors was used to categorize patients as responders or non-responders to pre-transplant LRT based on imaging performed before and after LRT. Overall survival (OS) and recurrence-free survival (RFS) were examined. OS at 3 years post-transplant was 74% for HCC-CCA and 87% for HCC. RFS at 3 years was 74% for HCC-CCA, and 87% for HCC. Among responders to LRT, the 3-year OS was 92% for HCC-CCA and 88% for HCC; among non-responders, 3-year OS was 43% for HCC-CCA and 83% for HCC. Higher 3-year OS was observed among HCC-CCA responders (77%) compared with HCC-CCA non-responders (23%). OS was similarly high among responders to pre-transplant LRT irrespective of tumor type. Radiologic response to LRT could potentially be used to select appropriate HCC-CCA patients for LT if the findings are validated in independent studies. |
Author | Habboush, Yacob Y Chase, Lori A Patel, Tushar Antwi, Samuel O Lee, David D |
Author_xml | – sequence: 1 givenname: Samuel O surname: Antwi fullname: Antwi, Samuel O organization: Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA – sequence: 2 givenname: Yacob Y surname: Habboush fullname: Habboush, Yacob Y organization: Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA – sequence: 3 givenname: Lori A surname: Chase fullname: Chase, Lori A organization: Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA – sequence: 4 givenname: David D surname: Lee fullname: Lee, David D organization: Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA – sequence: 5 givenname: Tushar surname: Patel fullname: Patel, Tushar email: patel.tushar@mayo.edu organization: Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA. Electronic address: patel.tushar@mayo.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31208646$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kF9LwzAUxfMwcXP6AXyRfIHO_GvaPo6iTihMxnwOaZa4SpuUJBP24mc3ZerDPRcu5xy4vxsws85qAO4xWuUcsUeEVxQlSUNWhFAyAwvMeZ4RXuI5uAnhEyFGc0yuwZxigkrO-AJ873QYnQ0aRgcbp1y20x-ds7KH-6P2cjzDN68PnYoBbk9RuUEHuDZRe9h0X0n3Xtow9tJGGVMOGudh7Ya2s_oAN3qU0Snd96de-qw-umRM9Up61Vk3yFtwZWQf9N3vXoL356d9vcma7ctrvW4yhWkeM6baAlWUUlOkH4ySuJKkzBVjZUFlWShDmOJFy6dzxZFRpKKMt1VyGFpJugT40qu8C8FrI0bfDdKfBUZi4icQFhM_MfETE7-UebhkxlM76MN_4g8e_QEFSnDY |
ContentType | Journal Article |
Copyright | Copyright © 2018 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved. |
Copyright_xml | – notice: Copyright © 2018 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved. |
DBID | NPM AAYXX CITATION |
DOI | 10.5604/01.3001.0012.2232 |
DatabaseName | PubMed CrossRef |
DatabaseTitle | PubMed CrossRef |
DatabaseTitleList | CrossRef PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 10 |
ExternalDocumentID | 10_5604_01_3001_0012_2232 31208646 |
Genre | Journal Article |
GroupedDBID | --- .1- .FO 0R~ 0SF 1P~ 23M 2WC 53G 5GY 77H AAEDW AAKDD AALRI AAXUO ABXHO ADBBV ADVLN AENEX AEVXI AEXQZ AFCTW AFJKZ AFRHN AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ APOWU BAWUL DIK EBD EBS EMOBN F5P FDB GROUPED_DOAJ GX1 M41 NCXOZ NPM OC. OK1 ON0 P2P ROL RSH SV3 TR2 Z5R AAYXX CITATION |
ID | FETCH-LOGICAL-c135t-4cb709333f7043fca19a285c44873a87cf24c67b69a28960fc29346b9c44f39a3 |
ISSN | 1665-2681 |
IngestDate | Thu Sep 26 18:04:24 EDT 2024 Sat Sep 28 08:36:40 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | HCC Recurrence-free survival Overall survival Loco-regional therapy LRT combined hepatocellular and cholangiocarcinoma |
Language | English |
License | Copyright © 2018 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c135t-4cb709333f7043fca19a285c44873a87cf24c67b69a28960fc29346b9c44f39a3 |
PMID | 31208646 |
ParticipantIDs | crossref_primary_10_5604_01_3001_0012_2232 pubmed_primary_31208646 |
PublicationCentury | 2000 |
PublicationDate | 2018-11-01 |
PublicationDateYYYYMMDD | 2018-11-01 |
PublicationDate_xml | – month: 11 year: 2018 text: 2018-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Mexico |
PublicationPlace_xml | – name: Mexico |
PublicationTitle | Annals of hepatology |
PublicationTitleAlternate | Ann Hepatol |
PublicationYear | 2018 |
SSID | ssj0043512 |
Score | 2.239529 |
Snippet | Combined hepatocellular-cholangiocarcinoma (HCC-CCA) is a rare liver malignancy distinct from either hepatocellular carcinoma (HCC) or cholangiocarcinoma.... Introduction and aim: Combined hepatocellular-cholangiocarcinoma (HCC-CCA) is a rare liver malignancy distinct from either hepatocellular carcinoma (HCC) or... |
SourceID | crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 969 |
Title | Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31208646 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyFeEHfGTX7giSihtZ04eawKqELdKk2d1PESxa7NKo0EbYmQeOAv8Jc5viRNOxCMl6hy0yPL5-u5-fMxQq-5YEJnXIYQy-uQMS3DAnLbcE3FKE7XJCPaJIpHx8nslH1cxavB4GePtdTUIpLff3uu5H-0CmOgV3NK9gaa7YTCAHwG_cITNAzPf9LxiSO42tsv5pWswhP12ZX2lq5ZgGFYrDeGr7FoapiBugom9lLwuaFj-M7mF0XZoxyCgYBkGcLQGTiqujKFfcNUDacmCS5BvDS3D5WVt-fX-jCf25_1a_WTsv62cdXnL426CBbR1uwJUTVXtrJzBqZZBGfdd9Pzwt35OK8uN8GkG_fMIcvFD95F_arFOPXH97aGNrHsOnddS2eJeQ9xcc8nO-brvrWHYI3ZEwwRHZnWq-BrI4h2yNa1tdv5ex6v4yFCBmSE5KNxbkQYgh_JjYhb6IDwLI6H6OB4ulp8ap07BJduA72dvtsoN0LeXpvHTqizk7TY4GV5D931WQeeOAjdRwNVPkC3jzyv4iH60SIJ1xXeQRL2SMItknCLJGyRhC2S8B6SMCAJt0jCf0XSI3T64f1yOgv9zRyhHNO4DpkU3JTCqOawJFrC37sgaSwh1-e0SLnUhMmEi8QMQ46sJUSVLBEZvKFpVtDHaFhWpXqKMGGpNj0oFeUFWysFATsE3Rm4FcXjQqpD9KZdxPyra8CS_1Fth-iJW-buVTomkLSz5NlNxDxHd7aYfYGG9WWjXkLsWYtXHg-_AJG2gmU |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Response+to+Loco-Regional+Therapy+Predicts+Outcomes+After+Liver+Transplantation+for+Combined+Hepatocellular-Cholangiocarcinoma&rft.jtitle=Annals+of+hepatology&rft.au=Antwi%2C+Samuel+O.&rft.au=Habboush%2C+Yacob+Y.&rft.au=Chase%2C+Lori+A.&rft.au=Lee%2C+David+D.&rft.date=2018-11-01&rft.issn=1665-2681&rft.volume=17&rft.issue=5&rft.epage=10&rft_id=info:doi/10.5604%2F01.3001.0012.2232&rft.externalDBID=n%2Fa&rft.externalDocID=10_5604_01_3001_0012_2232 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1665-2681&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1665-2681&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1665-2681&client=summon |